MedTrace Logo

Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer

NCT04701281 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-09-18

No results posted yet for this study

Summary

The treatment proposed in this trial is to administer intra-arterial chemotherapy to liver metastases from colorectal cancer when the blood flow to and from the liver has been isolated via balloon catheters through a vascular access system called the AVAS. The objective of this study is to evaluate the tumour response of repeated and isolated intra-arterial liver isolation oxaliplatin compared with the standard systemic chemotherapy (intravenous 5-FU + leucovorin + oxaliplatin \[FOLFOX\] or oral capecitabine with IV oxaliplatin \[XELOX\]).

Conditions

  • Liver Metastasis Colon Cancer

Interventions

COMBINATION_PRODUCT

Intra-arterial LIOX + Capecitabine

5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine

Sponsors & Collaborators

  • AllVascular

    lead INDUSTRY

Principal Investigators

  • Nick Pavlakis, A/Prof · GenesisCare, St Leonards

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-02
Primary Completion
2022-09-19
Completion
2022-10-19

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04701281 on ClinicalTrials.gov